The Use of Immunotherapy to Treat Melanoma
DOI:
https://doi.org/10.58445/rars.1243Keywords:
Melanoma, Cancer, Evasion mechanism, Pathogens, ImmunotherapyAbstract
Melanoma is a skin cancer that originates from a mutation in melanocytes. This review explores different factors of melanoma and how it evades the immune system. In addition, it also discusses immunotherapy for the treatment of melanoma through monoclonal antibodies and combination therapies.
References
Abbott, M., & Ustoyev, Y. (2019). Cancer and the Immune System: The History and Background of Immunotherapy. Seminars in oncology nursing, 35(5), 150923. https://doi.org/10.1016/j.soncn.2019.08.002
Eddy, K., & Chen, S. (2020). Overcoming Immune Evasion in Melanoma. International journal of molecular sciences, 21(23), 8984. https://doi.org/10.3390/ijms21238984
Heistein, J. B., Acharya, U., & Mukkamalla, S. K. R. (2024). Malignant Melanoma. In StatPearls. StatPearls Publishing.
Weiss, S. A., Wolchok, J. D., & Sznol, M. (2019). Immunotherapy of melanoma: facts and hopes. Clinical Cancer Research, 25(17), 5191-5201.
Plaschka, M., Benboubker, V., Grimont, M., Berthet, J., Tonon, L., Lopez, J., Le-Bouar, M., Balme, B., Tondeur, G., de la Fouchardière, A., Larue, L., Puisieux, A., Grinberg-Bleyer, Y., Bendriss-Vermare, N., Dubois, B., Caux, C., Dalle, S., & Caramel, J. (2022). ZEB1 transcription factor promotes immune escape in melanoma. Journal for immunotherapy of cancer, 10(3), e003484. https://doi.org/10.1136/jitc-2021-003484
NCT03470922
Knight, A., Karapetyan, L., & Kirkwood, J. M. (2023). Immunotherapy in Melanoma: Recent Advances and Future Directions. Cancers, 15(4), 1106. https://doi.org/10.3390/cancers15041106
NCT04068181
Gastman, B., Robert, C., Gogas, H., Rutkowski, P., Long, G. V., Chaney, M. F., Joshi, H., Lin, Y. L., Snyder, W., & Chesney, J. A. (2022). Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115. Journal of Clinical Oncology, 40(16_suppl), 9518. https://doi.org/10.1200/jco.2022.40.16_suppl.9518
Downloads
Posted
Categories
License
Copyright (c) 2024 Veronika Obideiko, Ashley
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.